Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
Covered in this story
Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.